{"id":499311,"date":"2021-05-27T07:33:12","date_gmt":"2021-05-27T11:33:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/"},"modified":"2021-05-27T07:33:12","modified_gmt":"2021-05-27T11:33:12","slug":"werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/","title":{"rendered":"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., May  27, 2021  (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc.\u00a0(Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET.<\/p>\n<p>Access to the live webcast of this event, as well as an archived recording, will be available under the \u201cEvents\u201d tab on the investor relations section of the Werewolf Therapeutics website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xqZ9WVdK5Sy2wfxxxYyjYoyw8JiL5-H5plmWlIPNmn7s3_pzcnCvzTW-GZ2m-w8XX4v_4kUNn91MFBtbFZbFwLEf3-4T-yAw_8zZA_e6n7S7QEb8DppwH6IYj3wOLRiim4jvzFeepKWoXG6e0U7T6wbQ9oAw6CVD-6QLC2fzwA9ptYKpRvsLA_PtWzpdiIqU\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.werewolftx.com\/news-and-events\/events<\/a>.<\/p>\n<p>\n        <strong>About Werewolf Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR\u2122 platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE\u2122 molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.<\/p>\n<p>To learn more visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4mSTdqQrERP16wOluO97XeT4dhyQDYq4QLdeswCSYrbVZFQ7h2Ht_2Xzye0WZ0Ck3QiAgReHPjR33uXy8CD5sBcRzPegyETFbm_mCXGLPcg=\" rel=\"nofollow noopener\" target=\"_blank\">www.werewolftx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Alan Lada<br \/>Solebury Trout<br \/>617.221.8006<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qGBi8Ow4xRmJIuk37Ft7pO9MRf2JhseYx8mO69IY2SBlBuP_-pDFiGUfB-yxoZJaqTaIqby2cBLCs0pwsThnSMlOef8GwkPc3N4g9x7plFE=\" rel=\"nofollow noopener\" target=\"_blank\">alada@soleburytrout.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Amanda Sellers<br \/>VERGE Scientific Communications <br \/>301.332.5574<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oCcj59JkCBcjwh3Uz0ACudMVm8PQHMXlruc-sdfKFFWb-FVxpLzPgPYCufvjLCz7SsERuCjlUmr9JtJAVZDMusOPUI5trIrhN3pvM3kjLH49eWwwBHCS8HebMuAXkOKJ\" rel=\"nofollow noopener\" target=\"_blank\">asellers@vergescientific.com<\/a><\/p>\n<p>\n        <strong>Company Contact:<br \/><\/strong>Ellen Lubman<br \/>Chief Business Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MuexjjLdPzYaJRDSa9yrXz_mIrVQAcKd3vVMYKv64xONF2ftNIhA7FXZaHpcesaxA0FowOeRkpPATHdtPDvXgC0ungUlXd2HUjaYc4EzQ0c=\" rel=\"nofollow noopener\" target=\"_blank\">elubman@werewolftx.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/96846efb-7168-4e71-97db-5366a9ab2c2d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc.\u00a0(Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET. Access to the live webcast of this event, as well as an archived recording, will be available under the \u201cEvents\u201d tab on the investor relations section of the Werewolf Therapeutics website at: https:\/\/investors.werewolftx.com\/news-and-events\/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499311","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc.\u00a0(Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET. Access to the live webcast of this event, as well as an archived recording, will be available under the \u201cEvents\u201d tab on the investor relations section of the Werewolf Therapeutics website at: https:\/\/investors.werewolftx.com\/news-and-events\/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s &hellip; Continue reading &quot;Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T11:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021\",\"datePublished\":\"2021-05-27T11:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/\",\"name\":\"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=\",\"datePublished\":\"2021-05-27T11:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) &#8212; Werewolf Therapeutics, Inc.\u00a0(Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET. Access to the live webcast of this event, as well as an archived recording, will be available under the \u201cEvents\u201d tab on the investor relations section of the Werewolf Therapeutics website at: https:\/\/investors.werewolftx.com\/news-and-events\/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s &hellip; Continue reading \"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-27T11:33:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021","datePublished":"2021-05-27T11:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/","name":"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=","datePublished":"2021-05-27T11:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4OSM0MjA1MDAwIzIyMDc3NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/werewolf-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499311"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499311\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}